Research Article Volume 01, Issue No. 02. 2025



THE MEDICAL JOURNAL OF CLINICAL RESEARCH

Breast Cancer Chemoprevention

[1] Mutiara, [1] Indah

[1] Faculty of Medicine, Sebelas Maret University, Surakarta City, Central Java, Indonesia

Correspondence : dr.mutiara183837@gmail.com

Article History :
Received date : 2024/10/25
Revised date : 2024/11/08
Accepted date : 2024/12/16
Published date : 2025/01/05

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The literature on breast cancer chemoprevention has witnessed substantial advancements, emphasizing the importance of personalized strategies tailored to individual risk profiles. The integration of molecular insights and tumor-specific risk models is pivotal for identifying high-risk individuals who would benefit most from chemoprevention. **Literature Review:** The need for effective preventive measures against various breast cancer subtypes, particularly estrogen-receptor-negative cancers, has been highlighted (C. Litzenburger and H. Brown, 2014). This diversification in target agents is crucial in light of the rising incidence of breast cancer and the challenges presented by aggressive subtypes (C. Litzenburger and H. Brown, 2014). Endocrine therapies, such as tamoxifen and aromatase inhibitors, have demonstrated efficacy in reducing breast cancer incidence, though considerations regarding long-term tolerability and survival benefits remain critical (J. Johnston and Cheung, 2018). The mechanistic evaluation of phytochemicals further reinforces the significance of natural agents in the chemopreventive landscape, highlighting their potential roles in inhibiting carcinogenesis. A comprehensive understanding of the diverse classifications of chemopreventive agents, including hormonal and dietary options, is essential for establishing their efficacy across various premalignant conditions (Suvarna et al., 2020). This holistic view of breast cancer prevention advocates for lifestyle modifications alongside pharmacological interventions, reflecting a contemporary understanding of risk reduction strategies. **Conclusion:** Recent research synthesizes the importance of genetic risk assessment and lifestyle changes, advocating for a combination of chemoprevention and surgical interventions for high-risk individuals (Tsukioki et al., 2023). Overall, the literature underscores a dynamic and multifaceted approach to breast cancer chemoprevention, emphasizing the integration of molecular insights, personalized strategies, and a comprehensive understanding of various preventive measures in the ongoing fight against breast cancer.

Keyword: Breast Cancer, Chemoprevention

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The literature on breast cancer chemoprevention has evolved significantly over the past decade, reflecting advances in understanding the mechanisms underlying the disease and the development of targeted preventive strategies. (Cazzaniga and Bonanni, 2012) emphasize the importance of a tumor-specific risk model to identify high-risk individuals for effective chemoprevention. Their insights highlight that the integration of molecular pathways and the identification of new drug targets are crucial for developing safer and more effective chemopreventive agents. This perspective sets the stage for a more personalized approach to breast cancer prevention, which is echoed in the subsequent literature.

(P Steward and Brown, 2013) further build on this foundation by discussing the shift in chemoprevention research towards selecting agents based on their mechanisms of action rather than solely on historical epidemiological data. They introduce innovative strategies such as Short-term Intermittent Therapy to Eliminate Premalignancy (SITEP), which targets specific genetic interactions, illustrating a promising direction for future studies. Their work underscores the necessity of identifying high-risk populations to enhance the efficacy of clinical trials, a theme that resonates throughout the literature.

In 2014, (C. Litzenburger and H. Brown, 2014) expand the discussion by addressing the need for preventive strategies against estrogen-receptor-negative breast cancer, a subtype that presents unique challenges. They explore various agents under investigation, including inhibitors targeting HER2-positive and triple-negative breast cancer, thereby broadening the scope of chemoprevention beyond the traditionally studied subtypes. This diversification of targets is critical as it aligns with the growing incidence of breast cancer and the demand for effective preventive measures.

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

(R Landis-Piwowar and R Iyer, 2014) contribute to the dialogue by examining the role of dietary phytochemicals and synthetic compounds in disrupting carcinogenic pathways. Their analysis reveals that primary chemoprevention can be achieved through dietary interventions, emphasizing the potential of non-pharmacological approaches in cancer prevention. This perspective is essential as it complements the pharmacological strategies discussed in earlier articles, advocating for a multifaceted approach to breast cancer chemoprevention.

(J. Johnston and Cheung, 2018) highlight the efficacy of endocrine therapies such as tamoxifen and aromatase inhibitors in reducing breast cancer incidence. They critically assess the balance between efficacy and tolerability, raising important questions about long-term survival benefits from chemoprevention strategies. This nuanced discussion reflects the ongoing evaluation of existing therapies and their implications for clinical practice.

The exploration of phytochemicals continues with (Younas et al., 2018), who provide a mechanistic evaluation of these compounds in breast cancer treatment. Their review emphasizes the potential of phytochemicals to inhibit various stages of carcinogenesis, reinforcing the significance of natural agents in the chemopreventive landscape.

In a more recent analysis, (Suvarna et al., 2020) focus on the diverse classifications of chemopreventive agents, including hormonal and dietary options. They underscore the importance of clinical trials in establishing the efficacy of these agents across various premalignant conditions, thereby contributing to a comprehensive understanding of chemoprevention.

(Del Fiol Manna et al., 2023) present a holistic view of breast cancer prevention, advocating for lifestyle modifications alongside chemoprevention. Their emphasis on personalized risk assessments and evidence-based strategies reflects a contemporary understanding of breast cancer risk reduction, aligning with the ongoing evolution in preventive approaches.

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Finally, (Tsukioki et al., 2023) synthesize current research on breast cancer prevention, highlighting the significance of genetic risk assessment and the role of lifestyle changes. Their work reiterates the urgent need for effective preventive strategies in light of rising breast cancer incidence, advocating for a combination of chemoprevention and surgical interventions for high-risk individuals.

This literature review illustrates the dynamic and multifaceted nature of breast cancer chemoprevention, underscoring the importance of integrating molecular insights, risk assessment, and personalized strategies in the ongoing fight against this prevalent disease.

LITERATURE REVIEW

The article "Breast Cancer Chemoprevention: Old and New Approaches" provides a comprehensive overview of the evolving landscape of chemoprevention in breast cancer, emphasizing the critical role of personalized medicine and molecular pathways in developing effective interventions. The authors highlight that the success of chemopreventive strategies hinges on the identification of high-risk individuals through a tumor-specific risk model, which is essential for tailoring preventive approaches to those most likely to benefit.

A significant point raised in the article is the necessity for rigorous preclinical drug testing to develop novel and safer chemopreventive agents. This is particularly important given the historical context where major adverse events in large randomized prevention trials have led to skepticism and reluctance regarding the acceptance of active chemoprevention agents among the public. The authors argue that safety must be a paramount consideration in the development of these agents to ensure their acceptance and utilization in clinical practice.

Furthermore, the article discusses the promising results of endocrine interventions, which serve as a vital starting point for further advancements in the field. They advocate for the integration of molecular approaches into both research and clinical practice, suggesting that such integration will enhance the personalization of treatment and the effectiveness of chemopreventive strategies. This aligns with the

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

broader trend toward personalized medicine, where treatments are tailored based on individual genetic and molecular profiles.

The article also underscores the importance of identifying new surrogate endpoints that leverage molecular pathways and drug activity targets. This approach could facilitate the development of rational, effective, and safe preventive drugs that can intervene at early stages of carcinogenesis. The authors posit that advancements in understanding molecularly targeted therapies will streamline chemoprevention research and ultimately lead to better outcomes for patients at risk of developing breast cancer.

The article "Cancer chemoprevention: a rapidly evolving field" provides a comprehensive overview of the advancements and future directions in the field of chemoprevention, particularly in the context of breast cancer. The authors highlight the emergence of new research targets, including key transcription factors such as Nrf2, NF-κB, and members of the STAT family, which play crucial roles in cellular responses to stress and inflammation. This focus on transcription factors is significant as their modulation could potentially lead to innovative therapeutic strategies aimed at preventing the progression of pre-neoplastic lesions.

A notable aspect of the article is the exploration of novel agents targeting the cyclin family of cell cycle regulators, specifically cyclin D1, D2, and D3. The abnormal expression of these cyclins in pre-neoplasia underscores their importance as potential therapeutic targets. The authors emphasize the need for further investigation into these agents, suggesting that their role in cell cycle regulation may offer new avenues for chemopreventive interventions in breast cancer.

The introduction of the Short-term Intermittent Therapy to Eliminate Premalignancy (SITEP) approach is particularly intriguing. The hypothesis that intermittent therapy could selectively induce apoptosis in premalignant cells has shown promising results in mouse models and is currently being tested in human breast cancer trials. This innovative strategy reflects a shift towards more dynamic treatment regimens that may enhance the efficacy of chemoprevention.

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Furthermore, the article discusses the transition from single-agent chemoprevention to combination therapies. The trial combining difluoromethylornithine and sulindac, which resulted in a 60% reduction in recurrence rates, exemplifies the potential benefits of this approach. This finding underscores the importance of exploring synergistic effects of multiple agents to improve outcomes in high-risk populations.

The authors also highlight the need for more extensive research into nutritionally derived agents, suggesting that these may play a vital role in chemoprevention strategies. The identification of high-risk individuals for clinical trials is another critical point raised, as it could enhance the precision and effectiveness of chemoprevention efforts. The authors advocate for the integration of clinico-pathological variables and molecular markers to better predict which patients may benefit from preventive interventions.

The article "Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer" offers a comprehensive overview of the evolving landscape of breast cancer chemoprevention, particularly focusing on estrogen-receptor-negative (ER-negative) subtypes. The authors articulate the critical need for effective preventive strategies, given the rising incidence of breast cancer globally and its status as the most prevalent cancer among women.

One of the key insights from the article is the established efficacy of agents such as tamoxifen, raloxifene, and exemestane in reducing the incidence of estrogen-receptor-positive breast cancer in high-risk women. However, the authors emphasize that distinct preventive strategies are necessary for different breast cancer subtypes, particularly for ER-negative breast cancers, which have historically posed a greater challenge due to their aggressive nature and lack of targeted therapies.

The article critically evaluates current research efforts aimed at identifying alternative mechanisms through which various biologically active compounds could mitigate the risk of breast cancer across all subtypes. The authors highlight

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

promising agents under investigation for the prevention of HER2-positive and triple-negative breast cancer, including inhibitors of the ErbB family receptors, COX-2 inhibitors, metformin, retinoids, statins, and poly(ADP-ribose) polymerase inhibitors. This breadth of potential preventive agents underscores the complexity of breast cancer biology and the necessity for tailored approaches to chemoprevention.

Moreover, the authors discuss the multifaceted nature of breast cancer prevention, which encompasses not only pharmacological interventions but also genetic screening, early detection methods such as mammography and breast MRI, and surgical options for high-risk individuals. This holistic approach to breast cancer management is essential for delaying the onset of malignancy and reducing the progression of premalignant cells to invasive disease.

The article "Cancer Chemoprevention: Current State of the Art" provides a comprehensive overview of the mechanisms and agents involved in cancer chemoprevention, with a particular focus on the disruption of molecular pathways that lead to carcinogenesis. The authors effectively outline the significance of both dietary phytochemicals and synthetic compounds in the prevention of cancer, emphasizing their roles in inhibiting the initiation of carcinogenic processes.

One of the key insights presented in the article is the identification of various molecular mechanisms that chemopreventive agents target. The authors discuss how these agents can mitigate DNA damage caused by reactive oxygen species, which is a critical factor in the development of cancer. Furthermore, they highlight the importance of inhibiting signal transduction pathways, particularly those involving NF-kB, which are often upregulated in cancerous cells. By addressing these pathways, chemopreventive agents can potentially delay or prevent the progression of cancer.

The article also emphasizes the role of epigenomic deregulation and the epithelial-mesenchymal transition in cancer metastasis. The authors suggest that chemopreventive agents can disrupt these processes, thereby reducing the

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

likelihood of metastatic progression. This is a significant contribution to the field, as it underscores the potential of chemoprevention not only in the early stages of cancer development but also in curbing the spread of established tumors.

Moreover, the review highlights the promise of dietary phytochemicals in primary chemoprevention. The authors provide examples of specific phytochemicals that have demonstrated efficacy in inhibiting the initiation of carcinogenesis, indicating a growing interest in the role of nutrition and lifestyle choices in cancer prevention. This aspect is particularly relevant in contemporary discussions around holistic approaches to health and disease prevention.

The article "Endocrine therapy for breast cancer: a model of hormonal manipulation" provides a comprehensive overview of the role of chemoprevention in breast cancer, particularly focusing on high-risk pathologies such as atypical ductal hyperplasia and lobular carcinoma in situ. The authors emphasize the significant findings from pivotal trials that support the efficacy of chemoprevention strategies, notably highlighting the reduction in breast cancer incidence among patients receiving tamoxifen, with a reported decrease of 44% in estrogen receptor (ER)-positive patients.

One of the critical insights from the article is the comparative efficacy of aromatase inhibitors (AIs) over tamoxifen in chemoprevention trials. This finding indicates a shift in the paradigm of chemopreventive strategies, suggesting that AIs may offer a more favorable risk-benefit profile. The authors underscore the necessity of balancing efficacy with tolerability, a vital consideration when recommending chemoprevention to patients, particularly given the potential side effects associated with long-term endocrine therapy.

Moreover, the article raises pertinent questions regarding the long-term implications of chemoprevention. While a reduction in breast cancer incidence is a significant outcome, the authors point out the need for further research to ascertain whether this translates into improved overall survival rates. This aspect is crucial,

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

as the ultimate goal of chemoprevention is not only to delay the onset of breast cancer but to enhance the longevity and quality of life of high-risk individuals.

The authors also highlight that young women at high risk are likely to derive the most benefit from chemoprevention strategies. This demographic focus is essential, as it directs clinical efforts towards populations that may experience the most significant impact from preventive measures. However, the article suggests that chemoprevention with endocrine therapy is only one component of a multifaceted approach to breast cancer prevention, indicating the necessity for integrating other strategies alongside hormonal manipulation.

The article "Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives" provides a comprehensive overview of the role of phytochemicals in the chemoprevention of breast cancer. The authors systematically explored recent literature, emphasizing the potential of various phytochemicals to influence breast cancer progression and prevention.

One of the key strengths of this review is its methodological rigor in sourcing relevant literature. The authors utilized multiple academic databases, including Google Scholar, PubMed, and Scopus, to gather recent articles from the past five years. This approach not only ensures a broad and updated understanding of the topic but also enhances the credibility of the findings presented. By focusing on keywords such as "breast cancer," "chemoprevention," and specific phytochemical names, the authors effectively narrowed down their search to pertinent studies that contribute to the understanding of phytochemicals in breast cancer management.

The article highlights several phytochemicals, detailing their mechanisms of action and potential therapeutic benefits. This mechanistic evaluation is crucial, as it provides insights into how these compounds may inhibit cancer cell proliferation, induce apoptosis, and modulate signaling pathways associated with cancer development. The authors discuss various classes of phytochemicals, such as flavonoids, terpenoids, and phenolic acids, and their respective roles in breast

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

cancer chemoprevention. This detailed analysis allows readers to appreciate the complexity and diversity of phytochemical actions in the context of breast cancer.

However, while the article presents a thorough review of the existing literature, it could benefit from a more critical evaluation of the limitations and challenges associated with phytochemical research. For instance, the variability in bioavailability, efficacy, and the potential for interactions with conventional therapies are significant factors that warrant further discussion. Additionally, the review could have addressed the need for more clinical trials to validate the preclinical findings and to establish standardized dosages for effective chemoprevention strategies.

The article "Chemopreventive Agents in Oral Premalignancy: A Medical Management Review" provides a comprehensive overview of the role of chemopreventive agents in the context of oral premalignancy, with significant insights applicable to breast cancer chemoprevention. The authors emphasize the potential of resveratrol as a chemopreventive agent, highlighting its ability to significantly reduce levels of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) in plasma. This reduction is critical as elevated levels of these factors are associated with increased cancer risk, including breast cancer.

The article systematically categorizes chemopreventive agents into four distinct groups: hormonal agents, medications, diet-related agents, and vaccines. This classification is particularly useful for understanding the multifaceted approaches to cancer prevention. For instance, hormonal chemopreventive agents such as tamoxifen and raloxifene have shown efficacy in reducing the risk of invasive breast cancer in postmenopausal women. The authors discuss the results from various clinical trials that validate the effectiveness of these agents in managing premalignant conditions, reinforcing their relevance in breast cancer prevention strategies.

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Moreover, the article underscores the essential characteristics of an ideal chemopreventive agent, which include negligible toxicity, high efficacy, low cost, and human acceptance. This criterion is pivotal for the development and acceptance of chemopreventive strategies in clinical practice. The discussion on the mechanisms through which these agents operate—specifically, their ability to block or delay carcinogen activation and reduce DNA damage—provides a solid foundation for understanding their role in cancer prevention.

However, while the article offers valuable insights into the efficacy of various chemopreventive agents, it could benefit from a more in-depth exploration of the specific mechanisms of action for each category of agents mentioned. Additionally, a discussion on the potential side effects and limitations of these agents in diverse populations would enhance the understanding of their application in clinical settings.

The article "Chemoprevention and Lifestyle Modifications for Risk Reduction in Sporadic and Hereditary Breast Cancer" provides a comprehensive overview of preventive strategies aimed at mitigating the risk of breast cancer. The authors emphasize the importance of lifestyle modifications, such as reducing excess body weight, limiting alcohol consumption, and increasing physical activity, as pivotal components in decreasing the global burden of breast cancer. This multifaceted approach underscores the necessity of individualized breast cancer risk assessments, which allow for tailored risk management strategies to be developed for women identified as being at increased risk.

A critical evaluation of the article reveals that the authors effectively integrate lifestyle changes with pharmacological interventions, highlighting the role of chemoprevention in women with elevated risk factors. Specifically, the article discusses the efficacy of tamoxifen, raloxifene, anastrozole, and exemestane in reducing breast cancer incidence among high-risk populations. The authors advocate for a personalized approach in selecting the most appropriate chemopreventive agent, taking into account individual risk factors and potential adverse effects associated with each medication. This nuanced perspective is

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

crucial, as it recognizes that the effectiveness and acceptability of chemoprevention can vary significantly among individuals.

Furthermore, the article aligns with the American Society of Clinical Oncology (ASCO) clinical practice guidelines, which recommend the use of these endocrine therapies for postmenopausal women at increased risk. The authors clarify that risk reduction agents are advised for individuals aged 35 and older, with tamoxifen retaining its status as the standard care for premenopausal women. This distinction is important, as it emphasizes the need for age-appropriate interventions and acknowledges the unique considerations for different demographic groups.

The integration of genetic counseling and testing into the risk management framework is another significant contribution of the article. For women with inherited pathogenic or likely pathogenic germline variants, the authors suggest that risk reduction surgery may be a beneficial option. This aspect of the article highlights the importance of a comprehensive risk reduction strategy that encompasses both medical and surgical options, particularly for those at the highest risk due to genetic predispositions.

The article "Current status and challenges of breast cancer prevention~DNA methylation would lead to groundbreaking progress in breast cancer prevention~" offers a comprehensive overview of the current landscape of breast cancer (BC) prevention strategies, emphasizing the critical need for effective chemoprevention and surgical options in light of the increasing incidence of BC among women.

The authors begin by highlighting the alarming trend of rising BC rates, positioning the disease as the most prevalent cancer among women. This context underscores the urgency of developing robust preventive measures. The article effectively categorizes prevention strategies based on risk assessment, noting that the most effective approach involves tailoring recommendations to individual risk levels. This personalized strategy is crucial, as both chemoprevention and surgical interventions come with potential side effects that must be carefully weighed against their benefits.

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The discussion on chemoprevention is particularly noteworthy. The authors assert that it is primarily suitable for women at moderate risk, while surgical options are reserved for those identified as very high risk. This delineation is essential for clinicians and patients alike, as it helps navigate the complex decision-making process surrounding BC prevention. The emphasis on lifestyle modifications—such as weight loss and increased physical activity—as universally applicable prevention strategies is a significant point. These recommendations are not only practical but also empower women to take proactive steps in reducing their risk of BC without the associated side effects of pharmacological or surgical interventions.

Moreover, the article delves into the advancements in genetic research, revealing that approximately 10% of BC patients harbor germline mutations that significantly elevate their risk. This insight is pivotal, as it advocates for genetic risk assessment and testing as integral components of BC prevention. The authors highlight the importance of genetic counseling for high-risk patients, which can facilitate early medical interventions that are crucial for improving survival outcomes. This proactive approach to screening, including the use of mammography and MRI for women with identified genetic mutations, aligns with contemporary practices in oncology and underscores the role of precision medicine in cancer prevention.

CONCLUSION

The literature on breast cancer chemoprevention has witnessed substantial advancements, emphasizing the importance of personalized strategies tailored to individual risk profiles. The integration of molecular insights and tumor-specific risk models is pivotal for identifying high-risk individuals who would benefit most from chemoprevention (Cazzaniga and Bonanni, 2012). This shift towards a more individualized approach is echoed in the exploration of novel therapeutic strategies, such as Short-term Intermittent Therapy to Eliminate Premalignancy (SITEP), which targets specific genetic interactions and reflects the ongoing evolution in chemoprevention research (P Steward and Brown, 2013).

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The need for effective preventive measures against various breast cancer subtypes, particularly estrogen-receptor-negative cancers, has been highlighted (C. Litzenburger and H. Brown, 2014). This diversification in target agents is crucial in light of the rising incidence of breast cancer and the challenges presented by aggressive subtypes (C. Litzenburger and H. Brown, 2014). Complementing pharmacological strategies, dietary interventions utilizing phytochemicals have emerged as promising avenues for primary chemoprevention, emphasizing the multifaceted nature of cancer prevention (R Landis-Piwowar and R Iyer, 2014).

Endocrine therapies, such as tamoxifen and aromatase inhibitors, have demonstrated efficacy in reducing breast cancer incidence, though considerations regarding long-term tolerability and survival benefits remain critical (J. Johnston and Cheung, 2018). The mechanistic evaluation of phytochemicals further reinforces the significance of natural agents in the chemopreventive landscape, highlighting their potential roles in inhibiting carcinogenesis (Younas et al., 2018).

A comprehensive understanding of the diverse classifications of chemopreventive agents, including hormonal and dietary options, is essential for establishing their efficacy across various premalignant conditions (Suvarna et al., 2020). This holistic view of breast cancer prevention advocates for lifestyle modifications alongside pharmacological interventions, reflecting a contemporary understanding of risk reduction strategies (Del Fiol Manna et al., 2023).

Recent research synthesizes the importance of genetic risk assessment and lifestyle changes, advocating for a combination of chemoprevention and surgical interventions for high-risk individuals (Tsukioki et al., 2023). Overall, the literature underscores a dynamic and multifaceted approach to breast cancer chemoprevention, emphasizing the integration of molecular insights, personalized strategies, and a comprehensive understanding of various preventive measures in the ongoing fight against breast cancer.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved

- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Cazzaniga, M. and Bonanni, B. "Breast Cancer Chemoprevention: Old and New Approaches." (2012). ncbi.nlm.nih.gov
2. P Steward, W. and Brown, K. "Cancer chemoprevention: a rapidly evolving field." (2013). ncbi.nlm.nih.gov
3. C. Litzenburger, B. and H. Brown, P. "Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer." (2014). ncbi.nlm.nih.gov
4. R Landis-Piwowar, K. and R Iyer, N. "Cancer Chemoprevention: Current State of the Art." (2014). ncbi.nlm.nih.gov
5. J. Johnston, S. and Cheung, K. L. "Endocrine therapy for breast cancer: a model of hormonal manipulation." (2018). [PDF]
6. Younas, M., Hano, C., Giglioli-Guivarc'h, N., and Haider Abbasi, B. "Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives." (2018). ncbi.nlm.nih.gov
7. Suvarna, C., CSK Chaitanya, N., Ameer, S., Inamdar, P., Alugubelli, S., and Bhagyanagar, A. "Chemopreventive Agents in Oral Premalignancy: A Medical Management Review." (2020). ncbi.nlm.nih.gov
8. Del Fiol Manna, E., Serrano, D., Aurilio, G., Bonanni, B., and Lazzeroni, M. "Chemoprevention and Lifestyle Modifications for Risk Reduction in Sporadic and Hereditary Breast Cancer." (2023). ncbi.nlm.nih.gov
9. Tsukioki, T., A. Khan, S., and Shien, T. "Current status and challenges of breast cancer prevention~DNA methylation would lead to groundbreaking progress in breast cancer prevention~." (2023). ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Clinical Research
Copyright © International Medical Journal Corp. Ltd. All rights reserved